Stay updated with breaking news from Assess Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four WeeksVEVYE® is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) DosingNASHVILLE, Tenn. & HEIDELBERG, Germany--(BUSINESS WIRE)...
– Data examines patient perspectives on treatment outcome measures used in phase 3 KONFIDENT trial of sebetralstat -– Additional data show the impact of HAE on mental health, daily activities, and quality of life of people living with HAE -CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharm...
Data provides patient perspectives on optimal treatment outcomes and quality-of-life challenges for people living with HAE - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical
/PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free...
HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye disease (DED). CyclASol has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improvemen...